A genetic marker is a DNA sequence with a known physical location on a chromosome. These markers can be used to link our DNA to a specific condition or disease. Doctors can use genetic testing to know if someone is susceptible to certain conditions, find out where peoples ancestors are from, and much more.
Many companies have emerged that claim they can make valuable recommendations based on an insubstantial understanding of the human genome. Some give diet and exercise advice, others even go as far to make wine selections or sleeping tips. Now, some Canadian business teams and researchers are using these genetic markers to possible risk of cannabis dependence and/or the cognitive side effects we might experience according to a recent Globe and Mail article.
Though there is some interesting science behind these DNA tests, some scientists are referring to the new line of diagnostic cannabis products as ‘Genetic Astrology’ in an attempt to discount the testing. The companies that create them, however, are simply trying to help patients get the right medicine. That is something that just simply isn’t easy in the current medical environment. After years of federal illegality, doctors aren’t trained on how to prescribe cannabis medicinally.
This is the exact gap that companies like MedReLeaf and AnantLife are trying to bridge, but experts in pharmacogenomics warn against introducing cannabis genetic tests to the public too soon. As we know, the cannabis plant is complicated, with over 500 compounds making up unique combinations in each cultivar. We don’t fully understand what each does and how it interacts with the receptors in our bodies.
This winter, MedReLeaf will be coming out with the ReleafDx, their own spin on genetic testing as a prescription tool for cannabis doctors. The ReleafDx is focused on helping doctors know what products will be right for them, and what the starting dose should be. The creators of the revolutionary new test know that we are still working to fully understand genetic science, but we need a system in place for our patients.
There is a market for products like the ReleafDx from MedReLeaf because at the moment, doctors don’t truly understand where to start with cannabis as a medicine.